Roche Stock

CHF254.10

0.59% yesterday

SIX Swiss Exchange, Jul 22, 05:31 pm CET

ISIN

CH0012032048

Symbol

ROG

Index

SMI, SMIM

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Roche Stock price

CHF254.10

-84.60 24.98% 5Y

SIX Swiss Exchange, Closing price Tue, Jul 22 2025

-1.50 0.59%

ISIN

CH0012032048

Symbol

ROG

Index

SMI, SMIM

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

CHF208.5b

Enterprise Value

CHF225.8b

Net debt

CHF17.3b

Cash

CHF17.3b

Shares outstanding

795.4m

Valuation (TTM | estimate)

P/E

24.8 | 12.3

P/S

3.4 | 3.2

EV/Sales

3.7 | 3.5

EV/FCF

15.0

P/B

6.6

Dividends

DPS

CHF9.70

Yield 1Y | 5Y

3.8% | 3.1%

Growth 1Y | 5Y

1.0% | 1.5%

Payout 1Y | 3Y

94.0% | 72.0%

Increased

25 Years

Financials (TTM | estimate)

Revenue

CHF60.5b | CHF64.2b

EBITDA

CHF20.4b | CHF25.3b

EBIT

CHF20.1b | CHF21.8b

Net Income

CHF8.3b | CHF16.6b

Free Cash Flow

CHF15.1b

Growth (TTM | estimate)

Revenue

3.0% | 6.1%

EBITDA

8.3% | 23.8%

EBIT

8.4% | 8.6%

Net Income

-28.0% | 100.1%

Free Cash Flow

31.8%

Financial Health

Equity Ratio

31.2%

Return on Equity

26.1%

ROCE

26.9%

ROIC

25.5%

Debt/Equity

1.1

EPS

CHF10.3

FCF per Share

CHF19.0

Short interest

Employees

103k

Rev per Employee

CHF590.0k

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Roche Stock Analysis

Unlock Scores for Free

27 Analysts have issued a Roche forecast:

13x Buy

48%

10x Hold

37%

More details on Analyst Estimates Including Price Targets

27 Analysts have issued a Roche forecast:

Buy

48%

Hold

37%

Sell

15%

Analyst Estimates with Stock Price Targets

Financial data from Roche

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	60,495 60,495	3% 3% 100%
- Direct Costs	15,783 15,783	1% 1% 26%
Gross Profit	44,712 44,712	4% 4% 74%
- Selling and Administrative Expenses	13,758 13,758	2% 2% 23%
- Research and Development Expense	13,042 13,042	1% 1% 22%
EBITDA	20,438 20,438	8% 8% 34%
- Depreciation and Amortization	351 351	4% 4% 1%
EBIT (Operating Income) EBIT	20,087 20,087	8% 8% 33%
Net Profit	8,277 8,277	28% 28% 14%

In millions CHF.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Roche Stock News

Negative

Reuters

●

about one hour ago

Roche pauses shipments of Elevidys gene therapy outside the US, Bloomberg News reports

Roche Holding AG paused all shipments of the controversial gene therapy Elevidys, Bloomberg News reported on Tuesday.

Neutral

GlobeNewsWire

●

about 6 hours ago

Roche's Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)

Basel, 22 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today its Board of Directors' decision to propose to shareholders a modernisation of Roche Holding Ltd's capital structure for approval at the Annual General Meeting to be held on 10 March 2026 ("2026 AGM"). The proposal includes the exchange of the existing non-voting equity securities (“Genussscheine”) for participation certif...

AD HOC NEWS

●

one day ago

Roche will Genussscheine durch Partizipationsscheine ersetzen

Roche CH0012032048 will seine Genussscheine durch Partizipationsscheine ersetzen.

More Roche News

Company Profile

Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Head office	Switzerland
CEO	Thomas Schinecker
Employees	103,249
Founded	1896
Website	www.roche.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now